LAX.SH
VENUS REMEDIES LIMITED·PHARMACEUTICALS 72.79·Pharmaceuticals & Biotechnology Companies
Price
1,702.5
+0.28%52W Range
Market Cap
₹2,275.73 Cr
Traded: ₹6.57 Cr (0.29%) 0.0x
Free Float: ₹1,101.00 Cr (0.60% of FF traded)
Volume · 60D trend
39.02 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +7.0% | +7.0% | +12.0% | -- | +20.0% | Accelerating |
| Profit | +51.0% | +22.0% | +57.0% | -- | +174.0% | Accelerating |
| Return | +33.0% | +30.0% | +83.0% | +203.0% | -- | Accelerating |
| ROE | +5.0% | +10.0% | +11.0% | -- | -- | Accelerating |
Quarterly Results
Mar 2026
27 MayDec 2025
29 JanSep 2025
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 259 | 180 | 193 | 137 | 195 | 177 | 170 | 109 | 195 | 143 | 168 | 95 | 156 | 117 |
| Expenses | 196 | 143 | 162 | 122 | 166 | 158 | 163 | 97 | 176 | 131 | 150 | 85 | 131 | 109 |
| Operating Profit | 63 | 38 | 31 | 15 | 29 | 18 | 8 | 11 | 19 | 12 | 18 | 10 | 25 | 8 |
| OPM % | 24.0% | 21.0% | 16.0% | 11.0% | 15.0% | 10.0% | 4.0% | 10.0% | 10.0% | 8.0% | 11.0% | 11.0% | 16.0% | 7.0% |
| Other Income | 5 | 3 | 2 | 3 | 7 | 12 | 8 | 2 | 4 | 2 | 3 | 2 | 3 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 7 | 6 | 8 | 8 | 7 |
| Profit Before Tax | 62 | 33 | 26 | 13 | 31 | 25 | 9 | 7 | 17 | 8 | 14 | 5 | 20 | 5 |
| Tax % | 23.0% | 24.0% | 24.0% | 24.0% | 32.0% | 21.0% | 61.0% | 82.0% | 40.0% | 12.0% | 31.0% | 77.0% | 44.0% | 28.0% |
| Net Profit | 48 | 26 | 20 | 10 | 21 | 20 | 4 | 1 | 11 | 7 | 10 | 1 | 11 | 3 |
| Exceptional Items | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 35.5 | 19.1 | 15.1 | 7.2 | 15.7 | 14.7 | 2.6 | 0.9 | 7.9 | 5.1 | 7.4 | 0.9 | 8.3 | 2.5 |
| Sales Growth (YoY) | 32.8% | 1.7% | 13.5% | 25.7% | 0.0% | 23.8% | 1.2% | 14.7% | 25.0% | 22.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 43.9% | -6.7% | 40.9% | -29.7% | 10.2% | 4.1% | 56.0% | -44.1% | 36.4% | -14.9% | 76.8% | -39.1% | 33.3% | -- |
| OP Growth (YoY) | 117.2% | 111.1% | 287.5% | 36.4% | 52.6% | 50.0% | -55.6% | 10.0% | -24.0% | 50.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 65.8% | 22.6% | 106.7% | -48.3% | 61.1% | 125.0% | -27.3% | -42.1% | 58.3% | -33.3% | 80.0% | -60.0% | 212.5% | -- |
| Profit Growth (YoY) | 126.0% | 103.0% | 474.0% | 687.0% | 100.0% | 84.0% | -65.0% | 3.0% | -5.0% | 108.0% | 86.0% | -83.0% | 4709.0% | -42.0% |
| EPS Growth (YoY) | 126.2% | 30.6% | 472.6% | 689.0% | 99.9% | 186.3% | -64.7% | 3.4% | -5.0% | 108.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 85.7% | 27.1% | 109.8% | -54.3% | 7.2% | 457.4% | 189.0% | -88.4% | 53.5% | -31.2% | 745.5% | -89.4% | 236.2% | -- |
| OP Margin | 24.3% | 21.1% | 16.1% | 10.9% | 14.9% | 10.2% | 4.7% | 10.1% | 9.7% | 8.4% | 10.7% | 10.5% | 16.0% | 6.8% |
| Net Margin | 18.5% | 14.4% | 10.4% | 7.3% | 10.8% | 11.3% | 2.4% | 0.9% | 5.6% | 4.9% | 6.0% | 1.1% | 7.0% | 2.6% |
| Material Cost % | 46.1% | 47.9% | 55.7% | 54.0% | 52.9% | 62.4% | 63.3% | 53.1% | 61.5% | 62.2% | 58.1% | 50.4% | 55.9% | 60.2% |
| Employee Cost % | 9.5% | 11.6% | 11.9% | 14.8% | 10.8% | 11.1% | 12.7% | 16.8% | 10.1% | 12.1% | 11.0% | 16.8% | 9.3% | 13.1% |
| P/S | 2.96 | 2.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 22.13 | 20.34 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.83 | 2.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2026 ,inter alia, to consider and approve This is to inform you that the ....
As per the pdf enclosed.
Copy of newspaper publication for AGM prior Notice.
Closure of Trading window
As per file enclosed.
As per enclosed file.
As per the file enclosed
Appointments & reappointments of directors.
As per file enclosed
As the file enclosed.
AS per file enclosed.
As per the pdf enclosed
Social media Post on KYC updation.
Board meeting is scheduled for 26th May 2026.
Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Board meeting scheduled for ....
Annual Secretarial Compliance report for the Year ended on 31st March as per Reg 24(A) of SEBI LODR.
Newspaper publication of Notice to shareholders about transfer of physical shares as per SEBI circular.
Disclosure of social media post on details about Transfer of physical shares.
Social Media post informing shareholder about limited period window for physical transfer of shares.
Compliance certificate under Reg 74(5) of SEBI DP regulations for the quarter ended on 31st March 2026.
Disclosure under reg 31(4) of SEBI SAST regulations 2011.
Closure of trading window
Social media Post pertaining to Transfer of physical shares.
Disclosure.
Copy of newspaper publication of UFR as on 31st December 2025.
Outcome of Board meeting dated 29th January 2026
Unaudited Standalone and Consolidated Financial Results as on 31st December 2025
Venus Remedies awarded with Rs.11,77,50,000 incentive under PLI scheme.
Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 ,inter alia, to consider and approve The meeting of Board of Directors ....
Update
Grant of Market Authorisation in Indonesia
Compliance
Copy of newspaper notice.
Closure of Trading window.
Social media Post
Status of Physical Transfer request.
Announcement as per captioned subject.
Conclusion of all pending income tax matters relating to earlier assessment years.
Social Media Communication.
Clarification on movement in volume.
The Exchange has sought clarification from Venus Remedies Ltd on November 20, 2025, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Social Media post
Unaudited Financial Results as on 30th September 2025
This has reference to the meeting of Board of Directors held on 10th November 2025 inter alia considered and approved Unaudited Financial Results (Standalone and Consolidated) for the quarter ....
Social media communication regarding special windows for re-lodgement of physical shares.
Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2025 ,inter alia, to consider and approve Board Meeting scheduled to be ....
SEBI Circular on transfer of Physical Shares-Monthly report.
Social media communication for re-lodgement of transfer request of physical shares.
Compliance under Reg 74(5) of SEBI(DP) Reg 2018.
Newspaper publication for opening of 6 months window for transfer of physical shares as per SEBI circular dated 2nd July 2025.
Annual Reports
14